Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB Study of Escalating Doses of REVLIMID in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma

NCT00901615 is registered in ClinicalTrials.gov with Lymphoma Study Association as lead sponsor.

NCT NCT00901615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00901615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB Study of Escalating Doses of REVLIMID in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma
Lead sponsor
Lymphoma Study Association
Phase
Phase 1/2
Overall status
Completed
Start date
January 6, 2009
Completion date
November 23, 2015
Enrollment
108 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, lymphoma, large b-cell, diffuse, mantle cell lymphoma, marginal zone lymphoma